Bridgebio Pharma Inc (BBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 502,076 | 221,902 | 9,303 | 77,648 | 69,716 |
| Cost of Goods | 20,962 | 3,878 | 2,446 | 3,434 | 3,114 |
| Gross Profit | 481,114 | 218,024 | 6,857 | 74,214 | 66,602 |
| Operating Expenses | 1,005,487 | 811,875 | 614,673 | 586,850 | 643,348 |
| Operating Income | -523,411 | -592,973 | -607,370 | -512,202 | -576,632 |
| Interest Expense | 178,241 | 99,290 | 81,289 | 80,438 | 46,778 |
| Other Income | -30,851 | 150,069 | 35,408 | 107,988 | 36,956 |
| Pre-tax Income | -732,503 | -542,194 | -653,251 | -484,652 | -586,454 |
| Income Tax | 435 | 1,153 | N/A | N/A | N/A |
| Net Income Continuous | -732,938 | -543,347 | -653,251 | -484,652 | -586,454 |
| Minority Interests | -8,007 | -7,585 | -10,049 | -3,469 | -23,915 |
| Net Income | $-724,931 | $-535,762 | $-643,202 | $-481,183 | $-562,539 |
| EPS Basic Total Ops | -3.78 | -2.88 | -3.95 | -3.26 | -3.90 |
| EPS Basic Continuous Ops | -3.83 | -2.92 | -4.01 | -3.29 | -4.06 |
| EPS Diluted Total Ops | -3.78 | -2.88 | -3.95 | -3.26 | -3.90 |
| EPS Diluted Continuous Ops | -3.83 | -2.92 | -4.01 | -3.29 | -4.06 |
| EPS Diluted Before Non-Recurring Items | -3.78 | -3.27 | -3.95 | -3.79 | -3.90 |
| EBITDA(a) | $-512,010 | $-579,434 | $-591,969 | $-505,431 | $-570,789 |